RECOMBINATE 1000 IU
Land: Israel
Språk: engelsk
Kilde: Ministry of Health
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
COAGULATION FACTOR VIII RECOMBINANT 1000 IU/VIAL
Tilgjengelig fra:
TEVA MEDICAL MARKETING LTD.
ATC-kode:
B02BD02
Legemiddelform:
POWDER FOR SOLUTION FOR INJECTION
Administreringsrute:
I.V
Produsert av:
BAXTER S.A., BELGIUM
Terapeutisk gruppe:
COAGULATION FACTOR VIII
Indikasjoner:
The use of Recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Recombinate is also indicated in the perioperative management of patients with haemophilia A. Recombinate is appropriate for use in children of all ages including the newborn. (Safety and efficacy studies have been performed in both previously treated and previously untreated children). The product in not suitable for the treatment of von Willebrand's disease.
Autorisasjon dato:
2010-07-01
